SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BSD Medical (Long Term Investment Oriented)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pleonastic who wrote (93)1/31/2013 11:19:13 PM
From: fwhco1 Recommendation  Read Replies (2) of 178
 
"...BSD Medical equipment was used for providing the heat for releasing the encapsulated drug..."

Ray, Celsion's HEAT trial was for RFA alone on tumors from>=3cm to <=7cm, and RFA with Thermodox. BSD's equipment was not involved in the HEAT trial, but will be used for the DIDNITY trial because from what I see, the BSD-500 is the only hyhperthermia machine available for surface heating. [Someone correct me on this if I am wrong.] See Dr. Poon's presentation available on the Celsion website.

Given that RFA is not too effective on tumors >3cm [my understanding is HCC, SOC for RFA, limits usage to <=3cm]. I was very surprised the endpoint wasn't achieved. To me that means the fault must lie with the chemo selected because Thermodox as a delivery system works.

A doctor in response to a Seeking Alpha article, said that doxorubicin was not effective on HCC and that it would not work in the HEAT trial. I asked him to expand on his statement, but he did not. I wish he had.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News